



## Correction: Newly Diagnosed Glioblastoma in Elderly Patients

Carlen A. Yuen<sup>1</sup> · Marissa Barbaro<sup>1,2</sup> · Aya Haggiagi<sup>1,3</sup>

Published online: 24 February 2022

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

### Correction: Current Oncology Reports

<https://doi.org/10.1007/s11912-022-01201-7>

The original version of this article unfortunately contained a mistake in the title of Table 1, which originally read “Marissa Barbaroelderly Glioblastoma Patient Trials.” The correct caption is shown below, and the original article has been corrected accordingly.

Table 1. Elderly Glioblastoma Patient Trials

There is also an error in the first sentence under ‘**Future Directions**’ section that should be corrected with the following.

Novel therapeutic approaches are needed in eGBM as prognosis remains dismal. Immunotherapy has revolutionized cancer therapy, but has yet to show survival benefit in GBM or eGBM [37].

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s11912-022-01201-7>.

---

✉ Aya Haggiagi  
amh2237@cumc.columbia.edu

Carlen A. Yuen  
cay2115@cumc.columbia.edu

Marissa Barbaro  
marissa.barbaro@nyulangone.org

<sup>1</sup> Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Hospital, 710 W 168th St, 9th Floor, New York, NY 10032, USA

<sup>2</sup> Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates – Mineola, NYU Long Island School of Medicine, NYU Langone Health, Mineola, NY, USA

<sup>3</sup> Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, NY, USA